+------------------------------------------------------------------------------+
Novartis CEO Says Acquisitions Possible: Schweiz am Sonntag 2013-12-08 10:50:22.866 GMT
By Elena Logutenkova Dec. 8 (Bloomberg) -- Novartis can spend $4b-$6b each yr on dividends, acquisitions, CEO Joseph Jimenez says in interview with Schweiz am Sonntag. * Says co. can spend $2b-$4b per acquisition in pharmaceuticals, eye-care and generics * Acquisitions for smaller divisions would be smaller: Jimenez * NOTE: Novartis sets $5b buyback as it seeks faster growth * NOTE: Novartis willing to Sell Roche stake * NOTE: Novartis starts strategic review of units, would consider $10b deal, Chairman Joerg Reinhardt said in Aug.
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editors: Amy Teibel, John Viljoen
To contact the reporter on this story: Elena Logutenkova in Zurich at +41-44-224-4101 or elogutenkova@bloomberg.net
To contact the editor responsible for this story: Frank Connelly at +33-1-5365-5063 or fconnelly@bloomberg.net
+------------------------------------------------------------------------------+
Geberit 2014 Buyback Possible, Baehny Tells Schweiz am Sonntag 2013-12-08 11:16:41.759 GMT
By Elena Logutenkova Dec. 8 (Bloomberg) -- Geberit will more probably start another share buyback next year rather than pay out special dividends, CEO Albert Baehny tells Schweiz am Sonntag in an interview. * Says nothing has been decided yet, topic to be discussed early 2014 with board of directors: Baehny * Co. not planning acquisitions, not in any talks: Baehny * NOTE: Geberit Quarterly Sales Gain on Northern European Recovery
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editors: Kim McLaughlin, Anthony Aarons
To contact the reporter on this story: Elena Logutenkova in Zurich at +41-44-224-4101 or elogutenkova@bloomberg.net
To contact the editor responsible for this story: Frank Connelly at +33-1-5365-5063 or fconnelly@bloomberg.net
+------------------------------------------------------------------------------+
Noble Expects Leviathan Production Before End 2017, Globes Says 2013-12-08 13:32:02.289 GMT
By Shoshanna Solomon Dec. 8 (Bloomberg) -- Development of Israel’s largest offshore natgas field will cost $8b, Noble Energy VP Keith Elliott says at conference in Tel Aviv, according to Globes website. * Leviathan production has been delayed by a year from original forecast due to delays in govt export policy: Elliott * “We plan to develop Leviathan at quickest pace we can”: Elliott * “There is huge potential for oil discoveries in the region”: Elliott
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editor: Robert Lakin
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at +972-3-542-7108 or ssolomon22@bloomberg.net
To contact the editor responsible for this story: Claudia Maedler at +971-4-364-1025 or cmaedler@bloomberg.net
+------------------------------------------------------------------------------+
Delek, Avner Decline as Noble Energy Says Leviathan Delayed 2013-12-08 13:37:15.613 GMT
By Shoshanna Solomon Dec. 8 (Bloomberg) -- Delek Group, which has stakes in Leviathan via Delek Drilling, Avner units, drops 3.4%, most since Nov. 18, to 1,320 shekels. * Avner -3.4%, most since Nov. 18, to 3.294 shekels * Delek Drilling -2.2%, most since Nov. 26, to 19.08 shekels * Ratio, also a partner in Leviathan, -2.7% * NOTE: Noble Expects Leviathan Production Before End 2017, Globes Says NSN MXHPLE6JTSEI <GO> * NOTE: Delek to Depend on Asset Sales as Gas Boon Slows: Israel Markets NSN MXA96J6S972Y <GO>
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editor: Robert Lakin
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at +972-3-542-7108 or ssolomon22@bloomberg.net
To contact the editor responsible for this story: Claudia Maedler at +971-4-364-1025 or cmaedler@bloomberg.net
Covidien Agrees to Buy Given Imaging for ~$860 Million --> $30 per share
Covidien to acquire all outstanding shares of developer of gastrointestinal diagnostics and monitoring products for $30 each in cash, according to a statement. NSN MXH8SCMEQTXC <GO> * Transaction subject to approval by Given Imaging shareholders and regulators; has been approved by both boards * Deal expected to be completed by Mar. 31 * Covidien will finance deal with cash on hand * Given Imaging will add $40m - $50m per quarter in incremental revenue * "Acquiring Given will enable Covidien to significantly expand its presence in a $3 billion GI market," Bryan Hanson, Group President, Medical Devices and U.S. for Covidien, said in the statement * NOTE: Given Imaging products include PillCam swallowed capsule endoscope * NOTE: Given shrs advance 22% on news to 6-yr high in Tel Aviv to 100 shekels, or $28.55
Link to Company News:COV US <Equity> CN <GO> Link to Company News:GIVN US <Equity> CN <GO>